

Validating Five Questions of Antiretroviral Nonadherence in a Public-Sector Treatment Program in Rural South Africa

Krisda Chaiyachati, M.P.H.,¹⁻³ Lisa R. Hirschhorn, M.D., M.P.H.,^{4,5} Frank Tanser, Ph.D., M.Sc., M.Sc.,² Marie-Louise Newell, Ph.D., M.Sc., M.B.,^{2,6} and Till Bärnighausen, M.D., Sc.D., M.Sc., M.Sc.^{1,2}

Abstract

Simple questions are the most commonly used measures of antiretroviral treatment (ART) adherence in sub-Saharan Africa (SSA), but rarely validated. We administered five adherence questions in a public-sector primary care clinic in rural South Africa: 7-day recall of missed doses, 7-day recall of late doses, a six-level Likert item, a 30-day visual analogue scale of the proportion of doses missed, and recall of the time when an ART dose was last missed. We estimated question sensitivity and specificity in detecting immunologic (or virologic) failure assessed within 45 days of the adherence question date. Of 165 individuals, 7% had immunologic failure; 137 individuals had viral loads with 9% failure detected. The Likert item performed best for immunologic failure with sensitivity/specificity of 100%/5% (when defining nonadherence as self-reported adherence less than “excellent”), 42%/55% (less than “very good”), and 25%/95% (less than “good”). The remaining questions had sensitivities $\leq 17\%$, even when the least strict cutoffs defined nonadherence. When we stratified the analysis by gender, age, or education, question performance was not substantially better in any of the subsamples in comparison to the total sample. Five commonly used adherence questions performed poorly in identifying patients with treatment failure in a public-sector ART program in SSA. Valid adherence measurement instruments are urgently required to identify patients needing treatment support and those most at risk of treatment failure. Available estimates of ART adherence in SSA are mostly based on studies using adherence questions. It is thus unlikely that our understanding of ART adherence in the region is correct.

Introduction

ADHERENCE TO ANTIRETROVIRAL TREATMENT (ART) is a crucial determinant of ART outcomes, including survival.¹⁻⁷ Nonadherence results in virologic and immunologic failure, clinical deterioration, and the development of viral resistance, complicating further treatment and increasing the risk of transmission of resistant virus.^{2,4,8-10} Valid methods to assess adherence are thus an essential component of ART programs.^{11,12} Questions on ART adherence are readily accessible, inexpensive, and easily and quickly administered in clinical settings.^{9,13} They are thus a feasible method to monitor adherence in sub-Saharan Africa (SSA), where neither the

human resources to perform more time-consuming adherence assessment (such as counting of antiretroviral pills or reviewing pharmaceutical records) nor the financial resources to conduct more costly assessment (such as electronic monitoring or monitoring of blood ART concentrations) may be available. In fact, in many of the public-sector ART programs in SSA, where three quarters of the world's four million people receiving ART live,¹⁴⁻¹⁶ questions on adherence are the only measure routinely used to assess adherence.¹⁷

However, these questions are only useful if they perform well in identifying nonadherent patients.^{10,18} But questions on ART adherence have rarely been validated as instruments to detect treatment failure in routine clinical settings in SSA's

¹Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts.

²Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa.

³University of Michigan Medical School, Ann Arbor, Michigan.

⁴Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.

⁵JSI Research and Training, Boston, Massachusetts.

⁶Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, London, United Kingdom.

public sector. The few studies that have been conducted found unsatisfactory performance of ART adherence questions in identifying patients who fail treatment. In 34 patients in routine care in Uganda, 3-day recall of missed doses and a visual analogue scale were weakly correlated with viral load level 12 weeks after ART initiation.²⁴ In 238 individuals in a routine clinic in Cameroon, 1-month recall of missed doses had a very low sensitivity in detecting patients with virologic treatment failure.²⁵ The 2006 WHO treatment guidelines for resource-limited settings do not provide clear recommendations regarding adherence measurement.¹² The scarcity of validated ART adherence questions in SSA is all the more surprising because our understanding of ART adherence in the region is largely based on patient responses to adherence questions,¹⁹ and interventions to increase adherence in routine care are commonly evaluated using adherence questions as outcome measures.^{20–23}

Some studies outside of SSA have demonstrated significant associations between self-reported adherence and viral load¹³ and antiretroviral (ARV) plasma concentrations.²⁶ However, other studies found that self-reported adherence was only weakly correlated with viral suppression and antiretroviral drug concentrations.^{27,28} It remains unclear whether questions on ART adherence are adequate instruments to assess adherence in routine clinical settings in SSA.^{15,16,29,30} We validate for the first time the performance of five commonly used ART adherence questions against a gold standard of treatment failure in a public sector, decentralized ART program in rural KwaZulu-Natal, South Africa.

Methods

Study setting

Patients were enrolled in KwaMsane clinic, the primary care clinic managing the largest number of HIV patients within a public-sector ART program in the Hlabisa subdistrict of KwaZulu-Natal, South Africa.³¹ The target population of the clinic lives in a rural town, or in the surrounding semi-urban and rural areas. ART is initiated at the clinic, free of charge, by a physician to all patients in the program with WHO stage IV disease or CD4 cell count less than 200 cells/mm³. Before ART initiation patients complete three treatment literacy sessions.¹⁷ The ART regimen, a first-line standard triple-drug regimen consisting of stavudine, lamivudine, and either efavirenz or nevirapine, is monitored and dispensed by nurses and counsellors at 2 weeks, 4 weeks, and at 4-week intervals thereafter. CD4 cell count and HIV viral load (VL) are routinely measured every 6 months. Approximately 6000 adult patients were initiated in the program between October 2004 and September 2008.³²

Adherence questions

After written informed consent, trained research staff with prior experience in HIV counseling and treatment administered five questions on ART adherence in isiZulu to patients attending the clinic. The five adherence questions comprising 7-day recall of missed doses, the number of doses missed by more than 2 hours in the past week, a Likert item with six levels of adherence over the past month, a 30-day visual analogue scale (VAS) of the proportion of doses missed, and a multiple-choice question with seven responses eliciting the

time of the most recently missed dose within discrete time intervals (Fig. 1). Except for the VAS, which was completed by the patient after receiving instructions, self-reported adherence questions were completed by the research staff. In addition to the adherence questions, the participants answered questions on demographic, socioeconomic, and behavioral factors, as well as on health status and health care seeking. Clinical data, CD4 counts, and VL data were extracted from the clinic files of each enrolled patient.

Samples

Patients who had received ART for at least 2 weeks, were not pregnant, and were not planning to stop ART in the next 6 months were enrolled between November 2007 and February 2008. Baseline analyses of the performance of adherence questions included all patients with a CD4 count ($n = 165$) or a viral load ($n = 137$) within ± 45 days of the date on which the adherence questions were administered.

Outcome definitions

Both immunologic and virologic failure definitions were based on WHO criteria for treatment failure,³³ as relevant for this study. Immunologic treatment failure was defined as less than 100 cells/mm³ after 6 months of ART. Virologic treatment failure was defined as a VL greater than 10,000 copies per milliliter after being on ART for over 6 months, or greater than 400 copies per milliliter after a previously undetectable viral load.

We started evaluating the performance of the different adherence questions, assuming that patients will fail treatment if they do not adhere near-perfectly,³⁴ i.e., considering any adherence level greater than 95% (for the 7-day recall of missed doses, the 7-day recall of late doses, and the VAS), any adherence level less than “excellent” (for the six-level Likert item), and any adherence level less than “never” (for the question about the time of the last missed dose) as “nonadherent.” We then assessed whether the adherence questions performed differently as diagnostic tests predicting treatment failure at alternative non-adherence cut-offs.³⁵ For the six-level Likert item on adherence, we used the additional nonadherence cutoffs less than “very good” and less than “good”; for the multiple-choice question on the time of the last missed dose, we used the additional cutoffs of any time more recent than “1 month” and more recent than “2 weeks.” For the remaining three questions, we used the additional cutoffs less than 85% and less than 75% of prescribed doses taken.

Statistical analysis

We used immunologic or virologic treatment failure as gold standard to evaluate the questions of nonadherence. Sensitivity, specificity, and corresponding 95% confidence intervals for varying cutoffs are reported for each self-reported adherence question. To assess the robustness of results to changes in the time of assessment of treatment failure relative to the date of the adherence questions, we also computed sensitivity and specificity for the samples of patients with biologic measures of treatment outcomes more than 3 months (resulting in samples of $n = 165$ for CD4 count and $n = 139$ for VL) or more than 6 months ($n = 124$ for CD4

TABLE 1. SAMPLE CHARACTERISTICS

	CD4 count sample N = 165	VL sample N = 137
Female (%)	76	81
Age (median [IQR])	38 (33–44)	38 (33–44)
Level of education		
None (%)	10	9
Primary school (%)	30	28
Secondary school or higher (%)	60	63
Travel time to clinic in minutes [median (IQR)]	30 (15–40)	30 (20–40)
Disability grant for HIV (%)	45	47
Disclosure of HIV status to family or friend (%)	100	100
Time on ARV in months [median (IQR)]	14 (9–25)	14 (9–25)
Treatment failure		
Immunologic failure (%)	7	—
Virologic failure (%)	—	9

IQR, interquartile range.

immunologic or virologic failure. Neither sensitivity nor specificity of the questions improved significantly when CD4 counts (or VLs) more than 3 months or more than 6 months after the date of the adherence question were used as gold standard in the analysis. Similarly, when we identified non-adherent individuals through an initial screening test (using the highly sensitive six-level Likert item) and then confirmed the diagnosis of nonadherence with a second adherence question (using one of the four highly specific questions), test performance did not improve significantly in comparison to the individual questions alone. None of the other possible combinations of adherence questions, including combinations of more than two questions, had better performance characteristics than the best-performing individual question included in the combination.

We further tested whether the performance of the adherence questions was better in particular subsamples than in the total sample by stratifying the analysis by sex, age (below 35 versus 35 or older), and education level (below secondary education versus secondary education or higher). While the performance of the questions varied across the strata, it did not improve significantly in any of the strata in comparison to the performance in the total sample. For instance, in the validation against CD4 count the performance characteristics of

TABLE 2. SENSITIVITY AND SPECIFICITY OF ADHERENCE QUESTIONS IN DETECTING TREATMENT FAILURE

Question item	Nonadherence cutoff	Number reporting nonadherence	Sensitivity	95% CI	Specificity	95% CI
<i>CD4 count sample (n = 165)</i>						
7-day recall of missed doses	<95%	6	0	0–26	96	92–99
	<85%	1	0	0–26	99	96–100
	<75%	1	0	0–26	99	96–100
7-day recall of missed doses ≥ 2 h	<95%	5	0	0–26	97	93–99
	<85%	1	0	0–26	99	96–100
	<75%	0	0	0–2	100	74–100
Six-level Likert item	<Excellent	157	100	74–100	5	2–9
	<Very good	73	42	15–72	55	47–63
	<Good	11	25	5–57	95	90–98
30-day VAS	<95%	7	0	0–26	95	91–98
	<85%	0	0	0–2	100	74–100
	<75%	0	0	0–2	100	74–100
Last missed dose	<Never	27	17	2–48	84	77–89
	<1 month	10	0	0–26	93	88–97
	<2 weeks	1	0	0–26	99	96–100
<i>VL sample (n = 137)</i>						
7-day recall of missed doses	<95%	4	0	0–25	97	92–99
	<85%	0	0	0–3	100	75–100
	<75%	0	0	0–3	100	75–100
7-day recall of missed doses ≥ 2 h	<95%	4	0	0–25	97	92–99
	<85%	1	0	0–25	99	96–100
	<75%	0	0	0–3	100	75–100
Six-level Likert item	<Excellent	131	92	64–100	3	1–8
	<Very good	59	23	5–54	55	45–64
	<Good	7	8	0–36	95	90–98
30-day VAS	<95%	3	0	0–25	98	93–100
	<85%	1	0	0–25	99	96–100
	<75%	0	0	0–3	100	75–100
Last missed dose	<Never	22	8	0–36	83	75–89
	<1 month	6	0	0–25	95	90–98
	<2 weeks	1	0	0–25	99	96–100

CI, confidence interval; VAS, visual analogue scale; VL, viral load.

the best-performing measure (the six-level Likert item with a nonadherence cutoff of less than “very good”) differed between the stratum with higher education level (50% sensitivity [95% confidence interval [CI] 16–84%]) and 54% specificity (95% CI 45–64%) and the total population (42% sensitivity [95% CI 15–72%]) and 55% specificity (95% CI 47–63%). However, these differences were neither substantial nor statistically significant.

Discussion

Questions on ART adherence are the most widely used instruments to measure adherence in treatment programs in SSA. We find that five questions commonly used in clinical research and practice to assess adherence, including the one currently used in the public sector in South Africa, perform poorly in detecting patients who fail treatment. Estimates of ART adherence in SSA are mostly based on responses to adherence questions.¹⁹ Our findings thus suggest that ART adherence in the region has been overestimated.

Reasons for ART failure other than nonadherence are generally rare in our context.³⁶ However, it is theoretically possible that a proportion of patients failed treatment despite current high levels of adherence, resulting in an underestimate of sensitivity. First, primary viral resistance could, of course, have resulted in treatment failure in perfectly adhering patients.^{37–39} But, according both to results from modeling studies⁴⁰ and local empirical evidence^{41,42} primary resistance was very rare in South Africa during the time of this study. Hence, we would not expect primary resistance to have affected our results.

Second, concomitant treatment for tuberculosis (TB) can interact with some antiretroviral drugs, leading to subtherapeutic ART concentrations.^{43,44} As Boulle et al.⁴⁵ showed, however, TB treatment only affects the probability of virologic failure in patients receiving the standard South African triple-drug regimen with nevirapine, which is only recommended for “pregnant women or women of child-bearing age, not on reliable contraception,”¹⁷ while it does not affect the regimen with efavirenz. The South African treatment guidelines thus specifically recommend the regimen containing efavirenz for all patients with TB coinfection.¹⁷ In all samples in this study, less than one quarter of the patients received a regimen with nevirapine, and less than one fifth of this group was simultaneously treated for TB. It is thus unlikely that TB treatment was responsible for a significant proportion of treatment failures in this study.

Third, HIV-related conditions may reduce ART blood-levels, leading to treatment failure despite perfect adherence. For example, HIV-associated enteropathy can cause vomiting, diarrhea, or malabsorption, reducing ART blood levels and manifesting as treatment failure.^{46,47} Finally, it has been suggested that some of the medicines given by traditional healers in KwaZulu-Natal can change the pharmacokinetics of ART.⁴⁸ However, all patients failing treatment according to either CD4 count or VL reported they did not receive care from the two types of traditional healers—*sangoma* and *inyanga*—who most commonly prescribe traditional medicines in this area.⁴⁹ Overall, it is thus unlikely that reasons for treatment failure other than nonadherence have biased our findings.

Another potential source of bias in our baseline results are the lag times between adherence and immunologic or viro-

logic response.⁵⁰ But our results remained essentially unchanged when we used only CD4 count or VL in the analyses that were measured 3 or 6 months after the date of the adherence assessment, demonstrating that lags are unlikely to have affected our findings.

A general limitation of most adherence questions is that they provide little information on the longitudinal pattern of adherence. For example, patients answering to the multiple-choice question that they missed the last dose “yesterday” could theoretically have missed one dose the day before but never missed a dose previously or they could have consecutively missed doses over several past days including the day before. Similarly, the VAS does not differentiate between all the different possible time patterns of nonadherence that imply any given proportion of doses missed over the past 30 days. Because the pattern by which patients fail to take their medication can have significant impact on their treatment outcomes and the development of resistance,^{37,39,51} the inability of self-reported adherence to capture adherence time patterns limits their utility in detecting patients with adherence problems. Once a patient has been identified as non-adherent, a more extensive dialogue with the patient may be necessary to identify the patterns and causes of non-adherence, in order to determine appropriate adherence support intervention.¹⁴

The location where an adherence question is asked may be an important determinant of the validity of the answer. For instance, when answering an adherence question in a public-sector clinic where ART are free of charge a patient may be more likely to fear negative consequences of reporting non-adherence (such as treatment discontinuation) than when answering the same question in a private-sector clinic where she pays for her ART. In this study in a public-sector clinic, we emphasized in the informed consent procedure that answers to the questions in the study questionnaire would be completely confidential and that reporting nonadherence would not lead to any negative consequences, in order to minimize intentional adherence misreporting. Nevertheless, future studies should examine whether the adherence questions used in this study perform better in identifying nonadherent patients when asked outside the setting of a public-sector clinic.

Adherence is a crucial determinant of ART success. Note, however, that different ART regimens may require different minimum levels of adherence to ensure successful treatment. A minimum adherence threshold of 95% of all prescribed doses taken was established initially as necessary for patients receiving an unboosted protease inhibitor and two nucleoside reverse transcriptase inhibitors to ensure the highest probability of viral suppression.⁷ More recent reports indicate that more moderate levels of adherence may be sufficient to ensure viral suppression for the majority of patients receiving boosted protease inhibitor-based regimens or nonnucleoside reverse transcriptase inhibitor-based regimens.^{52,53} Since most patients in public-sector ART programs in South Africa, such as the patients in our sample, receive non-nucleoside reverse transcriptase inhibitors (either efavirenz or nevirapine), it is possible that adherence levels below 95% are sufficient for treatment success in South Africa. Future studies need to establish the precise minimum adherence thresholds for the routine first-line ART regimens in this setting.

Independent of the precise minimum adherence required for treatment success, the ability to simply and validly

measure ART adherence is crucial for the long-term success of the recent initiatives to bring ART to scale in SSA. It is necessary to detect patients who are failing treatment and require additional support, in order to prevent the development of resistance. In the absence of resistance testing, it is further important to identify those who despite ongoing and reinforced adherence still fail treatment and thus require regimen change.⁵⁴ Our study shows that simple questions, which are commonly used in routine care, are insufficient for this purpose. It will be important to understand the reasons for the poor performance of these adherence questions in the public-sector treatment programs in South Africa, which could include social desirability bias, imperfect recall, or misinterpretations of the purpose of the questions.^{1,2,14,55-57} It will further be important to reassess our knowledge on ART adherence in SSA. Available estimates of ART adherence in the region are mostly based on studies using adherence questions. It is thus unlikely that our understanding of ART adherence in the region is correct.

Instruments that can be used in ART programs in SSA to identify individuals adhering imperfectly are urgently needed in order to provide additional support to prevent treatment failure and resistance development. Ideally such instruments would be neither costly nor time consuming. However, if instruments that are inexpensive and quick to administer, such as patient adherence questions or health worker estimates of adherence,⁵⁸ do not lead to valid adherence estimates, policy makers need to consider whether more resource-intensive measures, such as pill counts or electronic monitoring, should be routinely employed in public-sector treatment programs in SSA.

Acknowledgments

We thank the patients and program staff in the ART program in Hlabisa subdistrict for their support of this study. The study was financed through a pilot project grant from the National Institute of Aging (NIA), National Institutes of Health (NIH), through the Program on the Global Demography of Aging at Harvard University. The ART program received financial support from the US President's Emergency Fund for AIDS Relief (PEPFAR). Till Bärnighausen and Frank Tanser were supported by Grant 1R01-HD058482-01 from the National Institute of Child Health and Human Development (NICHD), NIH.

Author Disclosure Statement

No competing financial interests exist.

References

1. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. *Clin Infect Dis* 2001;33:1417-1423.
2. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. *AIDS* 2000;14:357-366.
3. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug anti-retroviral regimens. *J Acquir Immune Defic Syndr* 2000;23:386-395.
4. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. *AIDS* 1999;13:1099-1107.
5. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. *Clin Infect Dis* 2002;34:1115-1121.
6. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. *Clin Infect Dis* 2001;33:700-705.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000;133:21-30.
8. Hecht FM. Measuring HIV treatment adherence in clinical practice. *AIDS Clin Care* 1998;10:57-59.
9. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. *J Acquir Immune Defic Syndr* 2005;38:445-448.
10. Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. *AIDS Patient Care STDs* 2008;22:735-743.
11. World Health Organization, UNAIDS, UNICEF. Towards universal access : scaling up priority HIV/AIDS interventions in the health sector: Progress report 2009. Geneva: World Health Organization, 2009.
12. World Health Organization. Dept. of HIV/AIDS, Interim WHO Antiretroviral Treatment Working Group. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. Geneva: World Health Organization, 2006.
13. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. *AIDS Behav* 2006;10:227-245.
14. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. *J Infect Dis* 2008;197(Suppl 3):S272-278.
15. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. *AIDS* 2002;16:1835-1837.
16. Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. *Ann Intern Med* 2010;152:18-25.
17. National Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. Pretoria, South Africa: National Department of Health, 2010.
18. Llabre MM, Weaver KE, Duran RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. *AIDS Patient Care STDs* 2006;20:701-711.
19. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. *JAMA* 2006;296:679-690.

20. Jones DL, McPherson-Baker S, Lydston D, et al. Efficacy of a group medication adherence intervention among HIV positive women: The SMART/EST Women's Project. *AIDS Behav* 2007;11:79–86.
21. Jones DL, Ishii M, LaPerriere A, et al. Influencing medication adherence among women with AIDS. *AIDS Care* 2003;15:463–474.
22. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. *J Acquir Immune Defic Syndr* 2007;46:238–244.
23. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries: The Tanzanian experience. *Trop Med Int Health* 2009;14:1226–1232.
24. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *J Acquir Immune Defic Syndr* 2004;36:1100–1102.
25. Rougemont M, Stoll BE, Elia N, Ngang P. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: A prospective study at Yaounde Central Hospital, Cameroon. *AIDS Res Ther* 2009;6:21.
26. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. *Arch Intern Med* 2001;161:1962–1968.
27. Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. *J Acquir Immune Defic Syndr* 2002;30:324–334.
28. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. *J Acquir Immune Defic Syndr* 2008;48:216–219.
29. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. *J Acquir Immune Defic Syndr* 2006;43(Suppl 1):S149–155.
30. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. *J Acquir Immune Defic Syndr* 2001;26:435–442.
31. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. *Int J Epidemiol* (in press).
32. Mutevedzi PC, Lessells RJ, Heller T, Bärnighausen T, Cooke GS, Newell ML. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: Does rapid expansion affect patient outcomes? *Bull World Health Organ* 2010;88:593–600.
33. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2006 revision. Geneva: World Health Organization, 2006.
34. Machtiger EL, Bangsberg DR. Adherence to HIV antiretroviral therapy. <http://hivinsite.ucsf.edu/insite?page=kb-03-02-09> (Las accessed November 15, 2010).
35. Sullivan Pepe M. *The Statistical Evaluation of Medical Tests for Classification and Prediction*. Oxford: Oxford University Press, 2003.
36. Cressey TR, Lallemand M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. *Infect Genet Evol* 2007;7:333–342.
37. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. *AIDS* 2007;21:965–971.
38. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. *PLoS One* 2008;3:e2783.
39. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. *Clin Infect Dis* 2004;38:1311–1316.
40. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: Insights from empirical data and theoretical models. *AIDS* 2005;19:1–14.
41. Huang KH, Goedhals D, Fryer H, et al. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. *Antivir Ther* 2009;14:975–984.
42. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. *Antivir Ther* 2008;13:625–639.
43. Cohen K, van Cutsem G, Boule A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. *J Antimicrob Chemother* 2008;61:389–393.
44. Onyebujoh PC, Ribeiro I, Whalen CC. Treatment options for HIV-associated tuberculosis. *J Infect Dis* 2007;196(Suppl 1):S35–45.
45. Boule A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. *JAMA* 2008;300:530–539.
46. Brantley RK, Williams KR, Silva TM, et al. AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of *Cryptosporidium parvum*. *Braz J Infect Dis* 2003;7:16–22.
47. Lackner AA, Mohan M, Veazey RS. The gastrointestinal tract and AIDS pathogenesis. *Gastroenterology* 2009;136:1965–1978.
48. Mills E, Cooper C, Seely D, Kanfer I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. *Nutr J* 2005;4:19.
49. Truter I. African traditional healers. *SA Pharmaceut J* 2007(September):56–60.
50. Garcia F, Alonso MM, Romeu J, et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. *Early Anti-Retroviral Therapy Study*. *J Acquir Immune Defic Syndr* 2000;25:26–35.
51. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. *Curr HIV/AIDS Rep* 2007;4:65–72.
52. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. *J Acquir Immune Defic Syndr* 2007;45:4–8.
53. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. *Clin Infect Dis* 2006;43:939–941.

54. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. *Antivir Ther* 2007;12:83–88.
55. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. *PLoS Med* 2008;5:e109.
56. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. *Ann Intern Med* 2001;134:968–977.
57. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. *AIDS Behav* 2008;12:86–94.
58. Walshe L, Saple DG, Mehta SH, Shah B, Bollinger RC, Gupta A. Physician estimate of antiretroviral adherence in India: Poor correlation with patient self-report and viral load. *AIDS Patient Care STDs* 2010;24:189–195.

Address correspondence to:
Till Bärnighausen M.D., Sc.D., M.Sc., M.Sc.
Department of Global Health and Population
Harvard School of Public Health
665 Huntington Avenue
Boston, MA 02115

E-mail: tbaernig@hsph.harvard.edu

Africa Centre for Health and Population Studies
University of KwaZulu-Natal
P.O. Box 198
3935 Mtubatuba 3935
South Africa

E-mail: tbarnighausen@afriacentre.ac.za